key: cord-0910662-7g4qka75
authors: Edriss, Manar; Farshchian, Mehdi; Daveluy, Steven
title: Localized cutaneous reaction to an mRNA COVID‐19 vaccine
date: 2021-06-23
journal: J Cosmet Dermatol
DOI: 10.1111/jocd.14288
sha: 8109eab2450259bcb4fe47056bdb8d31b6b2f4ff
doc_id: 910662
cord_uid: 7g4qka75

The corona virus disease (COVID-19) is a novel disease that can lead to fatal outcomes in infected individuals. Messenger RNA (mRNA) vaccines are two of the three Food and Drug Administration (FDA) approved vaccines in the United States (US) to date. Disclosed side effects by the Centers for Disease Control and Prevention (CDC) included tiredness, headache, muscle pain, chills, fever, and nausea. 1,2 A variety of other adverse effects are continuously being reported in individual patients. We describe a case of localized cutaneous reaction to a mRNA vaccine.

Reported adverse reactions were more common after the second dose than the first dose and occurred more often in participants aged 18-55 years old. 1 The most common reported symptoms were fatigue, headache, muscle pain, chills, and injection site pain. 1 Symptoms that interfered with daily activity were found to be 0.6% of the participants. 1 The most recent analysis released by the CDC for allergic reactions reported 4393 adverse events through the Vaccine Adverse Event Reporting System (VAERS). 3 The nonanaphylactic allergic reactions that were reviewed included pruritus, rash, itchy/scratchy sensation in the throat, and mild respiratory symptoms. 

The authors declare no conflicts of interest.

Data sharing is not applicable to this article as no new data were created or analyzed in this study. 

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -United States

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases

Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series

Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers